BrainsWay to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

BrainsWay, a leader in non-invasive brain disorder treatments, announced that CEO Dr. Christopher von Jako will present at the H.C. Wainwright 6th Annual Israel Conference on November 12 at 7:00 AM ET. The company will also engage in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit on the same day.

BrainsWay specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) and has received FDA approvals for treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction. They are currently conducting clinical trials for various brain disorders.

CRESSKILL, N.J. and JERUSALEM, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 6^th Annual Israel Conference on Thursday, November 12 at 7:00 AM ET. The Company will also participate in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit held on November 12.

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit www.brainsway.com.

Contacts:
BrainsWay:
Judy Huber
SVP and Chief Financial Officer
Judy.huber@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

What is BrainsWay's presentation date at the H.C. Wainwright Conference?

BrainsWay's CEO will present on November 12 at 7:00 AM ET.

Where will BrainsWay participate in investor meetings on November 12?

BrainsWay will participate in one-on-one investor meetings at the Oppenheimer Fall MedTech Summit.

What technology does BrainsWay use for brain disorder treatments?

BrainsWay uses Deep Transcranial Magnetic Stimulation (Deep TMS) technology.

When did BrainsWay receive FDA marketing authorization for major depressive disorder?

BrainsWay received FDA marketing authorization for major depressive disorder in 2013.

What disorders is BrainsWay currently conducting clinical trials for?

BrainsWay is conducting clinical trials for psychiatric, neurological, and addiction disorders.